# Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPA

Study · id `cardio:ct-nct04479449` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04479449](<https://clinicaltrials.gov/study/NCT04479449>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04479449

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 178 participants.

## Technical summary

Registry record NCT04479449. Randomized; triple masking; primary purpose treatment. Start 2019-03-18 (actual); primary completion 2020-10-19 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 178 participants (enrolled count; ClinicalTrials.gov record NCT04479449, source copy `cardio:ctgov-nct04479449-2023-03-08`, retrieved 2026-10-26)
- Started: 2019-03-18 (actual) (ClinicalTrials.gov record NCT04479449, source copy `cardio:ctgov-nct04479449-2023-03-08`, retrieved 2026-10-26)
- Primary completion: 2020-10-19 (actual) (ClinicalTrials.gov record NCT04479449, source copy `cardio:ctgov-nct04479449-2023-03-08`, retrieved 2026-10-26)
- Completion: 2020-12-18 (actual) (ClinicalTrials.gov record NCT04479449, source copy `cardio:ctgov-nct04479449-2023-03-08`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT04479449, source copy `cardio:ctgov-nct04479449-2023-03-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04479449-2023-03-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPA
- Acronym: SP-8203-2002
- Condition: Ischemic Stroke
- Intervention (Drug): SP-8203
- Intervention (Drug): Placebo
- Lead sponsor: Shin Poong Pharmaceutical Co. Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Shin Poong Pharmaceutical Co. Ltd. (`cardio:org-shin-poong-pharmaceutical-co-ltd`)

## Provenance

Content hash: 5bf4b8bb3dcf92fc5f30123ac8858d71beef9904166c3585eb760d3b967dbba9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
